LaurettaIfeomaOdogwuMD

Oncology • Washington, DC

Physician

Join to view full profile

Dr. Odogwu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Odogwu's full profile

Already have an account?

Office
3800 Reservoir Rd NW
Washington, DC 20007
Phone+1 202-444-3700

Fax+1 202-444-3095

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1999 - 2002
St Francis Medical CenterResidency, Internal Medicine, 1996 - 1999
Royal College of Surgeons IrelandClass of 1989

Certifications & Licensure

VA State Medical License 2005 - 2026
MD State Medical License 2014 - 2025
DC State Medical License 1999 - 2022
NC State Medical License 2003 - 2019
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

147 citations
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal, Erin Larkins, Kirsten B. Goldberg
The Oncologist. 2018-06-01
10 citations
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
Philip Bonomi, Gideon M. Blumenthal, Andrea Ferris, David J. Stewart, Wendy Selig
Journal of Thoracic Oncology. 2018-06-01
48 citations
FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg, Gideon M. Blumenthal, Erin Larkins
The Oncologist. 2018-03-01